Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.64 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.63 |
| ▸ | CDK2 | P24941 | 3/20 | 0.63 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.63 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.63 |
| ▸ | FYN | P06241 | 1/20 | 0.62 |
| ▸ | IKBKB | O14920 | 1/20 | 0.58 |
| ▸ | PLK1 | P53350 | 3/20 | 0.57 |
| ▸ | AURKA | O14965 | 1/20 | 0.57 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.57 |
| ▸ | SYK | P43405 | 1/20 | 0.54 |
| ▸ | IGF1R | P08069 | 3/20 | 0.53 |
| ▸ | CDK1 | P06493 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7238444 | 0.91 | FYN (0.58) | KDRCCNA2CDK2CDK5CDK5R1 | |
| SCHEMBL6999967 | 0.91 | KDR (0.65) | KDRCCNA2CDK2CDK5CDK5R1 | |
| SCHEMBL7241504 | 0.91 | FYN (0.58) | KDRCCNA2CDK2CDK5CDK5R1 | |
| SCHEMBL7230962 | 0.90 | KDR (0.56) | KDRCCNA2CDK2CDK5CDK5R1 | |
| SCHEMBL7230996 | 0.88 | FYN (0.68) | KDRCCNA2CDK2CDK5CDK5R1 | |
| SCHEMBL7241524 | 0.88 | CDK2 (0.59) | KDRCCNA2CDK2CDK5CDK5R1 | |
| SCHEMBL6996576 | 0.87 | IGF1R (0.55) | KDRCCNA2CDK2CDK5CDK5R1 | |
| SCHEMBL6994864 | 0.85 | KDR (0.63) | KDRCCNA2CDK2CDK5CDK5R1 | |
| SCHEMBL7249337 | 0.85 | IKBKB (0.62) | KDRCCNA2CDK2CDK5CDK5R1 | |
| SCHEMBL7001192 | 0.85 | SYK (0.54) | KDRCCNA2CDK2CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323043-B2 | Derivatives of macrocyclic N-aryl-tricyclopyrimidine-2-amine polyethers as inhibitors of FTL3 and JAK | PIERRE FABRE MEDICAMENT (FR) | 2019-06-18 | — | — | US | disclosed |
| US-10323043-B2 | Derivatives of macrocyclic N-aryl-tricyclopyrimidine-2-amine polyethers as inhibitors of FTL3 and JAK | PIERRE FABRE MEDICAMENT (FR) | 2019-06-18 | — | — | US | disclosed |
| US-20170283432-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-TRICYCLOPYRIMIDINE-2-AMINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | PIERRE FABRE MEDICAMENT (FR) | 2017-10-05 | — | — | US | disclosed |
| US-20170283432-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-TRICYCLOPYRIMIDINE-2-AMINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | PIERRE FABRE MEDICAMENT (FR) | 2017-10-05 | — | — | US | disclosed |
| US-20170283432-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-TRICYCLOPYRIMIDINE-2-AMINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | PIERRE FABRE MEDICAMENT (FR) | 2017-10-05 | — | — | US | disclosed |
| EP-3189061-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-TRICYCLOPYRIMIDINE-2-AMINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | Pierre Fabre Médicament (FR) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016034637-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-TRICYCLOPYRIMIDINE-2-AMINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | PIERRE FABRE MEDICAMENT (FR) | 2016-03-10 | — | — | WO | disclosed |
| WO-2016034637-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-TRICYCLOPYRIMIDINE-2-AMINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | PIERRE FABRE MEDICAMENT (FR) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283432-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-TRICYCLOPYRIMIDINE-2-AMINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | JAK2, JAK3, JAK1 | KDR 900/4885CCNA2 809/4885CDK2 139/4885 |
| US-10323043-B2 | Derivatives of macrocyclic N-aryl-tricyclopyrimidine-2-amine polyethers as inhibitors of FTL3 and JAK | JAK2, JAK3, JAK1 | KDR 900/4885CCNA2 809/4885CDK2 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.